Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Guardant Health Inc GH

Healthcare
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer... see more

Recent & Breaking News (NDAQ:GH)

Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic

Business Wire July 20, 2021

AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding Round

PR Newswire July 19, 2021

Guardant Health to Report Second Quarter Financial Results on August 5, 2021

Business Wire July 13, 2021

Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling

Business Wire June 22, 2021

CORRECTING and REPLACING Study Shows Guardant Reveal(TM) Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity

Business Wire June 18, 2021

CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers

Business Wire June 18, 2021

Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer

Business Wire June 8, 2021

Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer

Business Wire June 4, 2021

Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen's LUMAKRAS(TM) (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer

Business Wire May 28, 2021

Guardant Health Files Lawsuit Against Natera for Misleading Oncologists

Business Wire May 28, 2021

Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen's RYBREVANT(TM) (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Business Wire May 21, 2021

Guardant Health to Participate in Upcoming June Investor Conferences

Business Wire May 20, 2021

Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers

Business Wire May 19, 2021

Guardant Health Reports First Quarter 2021 Financial Results

Business Wire May 6, 2021

Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer

Business Wire May 3, 2021

Study Shows Guardant Reveal(TM) Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity

Business Wire April 30, 2021

Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference

Business Wire April 29, 2021

Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer

Business Wire April 27, 2021

Guardant Health to Report First Quarter Financial Results on May 6, 2021

Business Wire April 12, 2021

Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers

Business Wire April 10, 2021